RxDoctor Payments Data

Erin Caves, NP

Family · Macon, GANPI 1427364611

Payments from drug & device makers

$5,653in general payments, 2019–2025

Across 267 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sekisui Diagnostics LLC$935
  • Novo Nordisk$897
  • AbbVie$432
  • Pfizer$326
  • Amgen$273
  • AstraZeneca$206
  • plus $3K from 47 others

What the payments were for

  • Food & beverage$4,63382%
  • Education$852%
  • Gifts$93517%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,653 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$105,508
Medicare patients
439
Services billed
2,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate20$27,348
MounjaroTirzepatide18$27,156
FarxigaDapagliflozin Propanediol26$26,995
EliquisApixaban29$26,392
OzempicSemaglutide17$26,026
EntrestoSacubitril/Valsartan11$11,753
Tresiba Flextouch U-100Insulin Degludec13$8,766
Colesevelam Hcl15$3,412
Pregabalin39$2,348
Atorvastatin Calcium165$1,558
Rosuvastatin Calcium115$1,557
Omeprazole103$1,393
Nebivolol Hcl19$1,306
Levothyroxine Sodium145$1,157
Bupropion XlBupropion Hcl45$1,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$129$27,15618 claims
AstraZenecaFarxiga$206$26,99526 claims
PfizerEliquis$326$26,39229 claims
Novo NordiskOzempic$897$26,02617 claims
NovartisEntresto$191$11,75311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →